


## Claims

1. A combination comprising a benzo[g]quinoline derivative and/or a pharmaceutically acceptable salt thereof, and a prostaglandin derivative and/or a pharmaceutically acceptable salt thereof.

2. A combination of claim 1, wherein said benzo[g]quinoline is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof




wherein

A and B are each H or form together an additional bond,

X is CH<sub>2</sub> or CO,

Y is O, S, NR<sub>1</sub> (R<sub>1</sub> being H or lower alkyl), CH<sub>2</sub> or O-CH<sub>2</sub>, and

R is of formula (a), (b), (c), (d), (e), (f), (g), (h) or (i).



R<sub>1</sub> being H or lower alkyl,


R<sub>2</sub> being H, lower alkyl, or thienyl, e.g. 2-thienyl,

Z<sub>1</sub> being O or S,

Z<sub>2</sub> being CH or N,

in free base or acid addition salt form,

and wherein said prostaglandin derivative is a compound of formula (II) and/or a pharmaceutically acceptable salt thereof,



wherein G denotes OH, lower alkoxy, amino-lower-alkyl, ,






A and B are each H or form together an additional bond,

L is CO, CHOR<sub>1</sub> (R<sub>1</sub> being H or lower alkyl),


M is O, S, (CH<sub>2</sub>)<sub>n</sub>, (n being from 1 to 6),

Q is H or Ar, Ar being preferably phenyl which is unsubstituted or substituted one or more times by halogen, hydroxy, lower alkoxy, cyano, halo-lower-alkyl, e.g. trihalomethyl.


3. Combination of claim 1, wherein said benzo[g]quinoline is any compound selected from the group of:

R<sub>1</sub> = H and CH<sub>3</sub>R<sub>1</sub> = H and CH<sub>3</sub>


and wherein said prostaglandin is any compound selected from the group of:




Latanoprost




Bimatoprost



Travoprost




Isopropyl Unoprostone



Ketolatanoprost

4. A combination of claim 1, wherein said benzo[g]quinoline is a compound of formula (I), and/or a pharmaceutically acceptable salt thereof, A and B are each H or form together an additional bond,




wherein

X is CH<sub>2</sub>

Y is S, and

R is of formula (e), (f), or (h),



R<sub>1</sub> being H or lower alkyl,


Z<sub>1</sub> being S,

Z<sub>2</sub> being CH or N, and


R<sub>2</sub> being H, or lower alkyl.

5. A combination of claim 4, wherein the prostaglandin is selected from Latanoprost, Travaprost, Bimatoprost and Ketolatanoprost, preferably from Latanoprost and Travaprost, more preferably from Latanoprost.


6. A combination of claim 1 which comprises



7. A combination of claim 1 which comprises



8. A combination of claim 1 which comprises



9. Use of a combination in accordance to any of claims 1 - 8 in the manufacture of a medicament for the treatment of glaucoma, e.g. being based upon elevated levels of IOP.

10. Method to treat and or prevent glaucoma in a subject, which method comprises the administration of a medicament to said patient, which medicament comprises a benzo[g]quinoline derivative and a prostaglandin derivative.
11. Method of claim 5 wherein said subject is suffering from elevated levels of IOP.
12. Method of treating normal tension glaucoma (NTG), which method comprises the administration of a medicament to said patient, which medicament comprises a benzo[g]quinoline derivative and a prostaglandin derivative.
13. Method of claim 12, wherein the chorio-retinal and/or optic nerve blood flow of said patient is impaired.
14. Method of claim 10, wherein said administration is topical ocular administration.
15. Combination of claim 1, which is an ophthalmic composition.
16. Combination of claim 15, which is an ophthalmic insert.
17. Combination of claim 1 - 2, wherein the compounds of formula (I) and (II) are present in a ratio of from 50:1 up to 1:50.